Tocilizumab, An IL-6 Receptor Antibody, As Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Phase of Trial: Phase IV
Latest Information Update: 27 Dec 2018
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Mar 2017 Status changed from active, no longer recruiting to completed.
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.